US SEC subpoenas Lilly in widened probe of compliance with overseas antibribery law
This article was originally published in Scrip
Executive Summary
In its latest regulatory filing, Lilly has reported new developments regarding a widened probe by the US Department of Justice (DoJ) and the US Securities and Exchange Commission (SEC) that it had first revealed in February 2009. The issue relates to its subsidiaries' compliance with a federal law, known as the US Foreign Corrupt Practices Act of 1977 (FCPA), which prohibits bribery of foreign officials.